The combination of amenorrhoea, galactorrhoea, and hyperprolactinaemia in a young woman usually suggests that she has a prolactin secreting adenoma of the anterior pituitary gland. Primary autoimmune thyroid failure, however, is common in young women and may also be associated with hyperprolactinaemia and with galactorrhoea in those whose breasts have been exposed to oestrogen. Hypothyroidism in patients with the amenorrhoea and galactorrhoea syndrome is usually suggested by appropriate symptoms and clinical signs, and treatment with thyroxine renders the patient euthyroid, with resolution of the hyperprolactinaemia. We report on a patient who presented with amenorrhoea, galactorrhoea, hyperprolactinaemia, and suprasellar enlargement of the pituitary. Although she was clinically euthyroid, treatment with thyroxine resulted in resolution of her symptoms and hormonal and radiological abnormalities within six weeks.
Patients with hyperprolactinaemia, with or without pituitary enlargement, should undergo assessment ofthyroid function even if clinically euthyroid !tg levonorgestel and ethinyloestradiol 30 Ltg) and had regular withdrawal bleeds. In 1983 after a planned pregnancy she delivered a healthy girl, but the puerperium had been complicated by severe postnatal depression and she remained amenorrhoeic for one year and had then had six months' oligomenorrhoea.
Investigation elsewhere showed hyperprolactinaemria (prolactin concentrations of 762 and 1288 mU/l (normal <420 mU/l)) and a normal pituitary fossa on plain skull radiography. Her mother had been treated for hypothyroidism.
Responses ofgrowth hormone, cortisol, prolactin and thyroid stimulating hormone to hypoglycaemia (0-1 U insulin kg), domperidone (10 mg intravenously), and thyrotrophin releasing hormone (200 pg intravenously) Cortisol and growth hormone responses to hypoglycaemia were normal, but there was no rise in prolactin concentrations. The cortical response to hypoglycaemia was only just within the normal range, but an intact pituitary-adrenal axis was confirmed by a normal rise in urinary excretion of 17 hydroxycorticosteroids during a high dose metyrapone test. Basal thyroid stimulating hormone concentrations were appreciably raised (normal <5 mUIl), and there was a notable increase in both thyroid stimulating hormone and prolactin concentrations after administration ofthe dopamine antagonist domperidone. Similarly, the responses of thyroid stimulating hormone and prolactin to thyrotrophin releasing hormone were both exaggerated. Surprisingly, in view of the patient's apparent clinical state, the serum free thyroxine concentration was low (2 pmolll (0-16 ngl100 ml); normal range 8-1661 26 pmolIl (0-6-2-0 ng/100 ml)) and thyroid microsomal antibodies measured by haemagglutination of red cells were positive at 1/6400. The serum concentration of 17-fl oestradiol was low (45 pmol/l (12 pg/ml); normal follicular phase >70 pmol/l (>19 pg/ml)), and there was no evidence of ovulation (serum progesterone concentration <2 nmol/l (<0-6 ng/ml)).
We concluded that the patient had primary autoimmune thyroid failure with associated hyperprolactinaemia and that the pituitary enlargement was due to thyrotrophic hyperplasia. Replacement treatment with thyroxine was begun, increasing to 100 ig daily. One month later the serum free thyroxine concentration was 18 pmolAI (14 ng/100 ml) and the thyroid stimulating hormone concentration had fallen to 21 6 mU/1. Serum prolactin concentration was normal at 350 mU/l. The patient felt no different as a result of treatment, although there was no galactorrhoea on expression. Computed tomography showed a normal pituitary gland with homogeneous uptake after contrast and no evidence of suprasellar extension (figure). Two months after the start of thyroxine treatment the serum free thyroxine concentration was 25 pmolIl (1-9 ng/100 ml) and the serum thyroid stimulating hormone concentration was normal at 0 6 mU/l. Menstruation occurred six weeks after thyroxine was started, and subsequent cycles were regular. The response of prolactin to hypoglycaemia was not reassessed after thyroxine treatment because we could not justify further insulin induced hypoglycaemia in a patient with normal anterior pituitary function. 
Discussion
This case emphasises that thyroid state must be assessed in all patients with amenorrhoea and galactorrhoea and hyperprolactinaemia, even if they seem to be clinically euthyroid. It also illustrates the degree of suprasellar extension that may occur in such cases and the rapidity of response to L-thyroxine. It is well known that in longstanding hypothyroidism the pituitary may be enlarged and may show suprasellar extension.' 2The lack of clinical features of hypothyroidism, in our patient, however, together with the manner of presentation, might have led the unwary to misdiagnose the condition and treat her inappropriately. The increased pituitary size was presumably a result of thyrotroph hyperplasia,3 I although it is not possible to know whether a true thyrotroph feedback adenoma was also present. "Feedback" adenomas secreting thyroid stimulating hormone have been associated with primary thyroid failure,58 but these also resolve with adequate thyroxine replacement treatment. Although the suprasellar extension had resolved after one month's treatment, the serum thyroid stimulating hormone concentration was still raised, though below its initial value. In similar patients the fall in prolactin concentration was reported to take longer than the fall in thyroid stimulating hormone concentration,9 but in our case prolactin concentrations were normal before thyroid stimulating hormone concentrations. These responses show that the rapidity with which pituitary hyperplasia resolves with adequate and appropriate replacement treatment.
In euthyroid subjects with adenomas that secrete prolactin there is a blunted (< 100%) prolactin and exaggerated thyroid stimulating hormone (>2 mU/l) response to acute dopamine antagonism with domperidone compared with the response in control subjects.'°" Our patient showed an exaggerated thyroid stimulating hormone response to domperidone compatible with a prolactinoma or primary hypothyroidism,'0 but in addition the prolactin response was greatly exaggerated, which militates against the presence of a prolactinoma but does not exclude it. Similar responses occurred after administration of thyrotrophin releasing horione.
The cause of hyperprolactinaemia in patients with primary hypothyroidism is unknown. In this patient it is unlikely that the suprasellar extension caused appreciable compression of the stalk as dopamine receptor blockade resulted in considerable increases in circulating concentrations of thyroid stimulating hormone and prolactin, which means that hypothalamic dopamiine was still reaching the anterior pituitary gland via the hypophysial-portal system. We recently reported that patients with stalk compression hyperprolactinaemia owing to lesions that are not prolactinomas show reduced or absent thyroid stimulating hormone responses to domperidone. ' 
